Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

计划入组 31 人 · 首次发布于 2021 年 11 月 9 日

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

计划入组 20 人 · 首次发布于 2024 年 5 月 1 日

Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer

计划入组 150 人 · 首次发布于 2015 年 4 月 3 日

Ovarian Cancer (ErVimmune)

Oncoquest-Ovarian cancer

Ovarian Cancer(Dewpoint)

HCW Biologics

United States

CENTER WEST CANCER

United States

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

China

Avutometinib-Defactinib Combination Shows 45% Response Rate in Low-Grade Serous Ovarian Cancer

Avutometinib Plus Defactinib Shows Promise in Recurrent Low-Grade Serous Ovarian Cancer

Avutometinib Plus Defactinib NDA Filed for KRAS-Mutant Low-Grade Serous Ovarian Cancer